Dihydropyrimidines Emerge as Promising Dual‐Acting Inhibitors Targeting Acetylcholinesterase and Monoamine Oxidases for Alzheimer's and Other Neurological Disorders DOI Open Access

Maria Saleem Khan,

Talha Islam,

Muhammad Umer Farooq

et al.

ChemistrySelect, Journal Year: 2025, Volume and Issue: 10(6)

Published: Feb. 1, 2025

Abstract The pathogenesis of Alzheimer's disease (AD) is multifaceted, and more than one factor deemed responsible for its genesis progression. Hence, the multi‐target approach seems plausible en route to development therapeutics targeting in particular, other neurological disorders, general. Among major factors AD are acetylcholinesterase monoamine oxidase enzymes. Acetylcholine an important neurotransmitter that plays a role processing memory learning. Deficiency this observed patients AD; largely attributed increased expression enzyme (AChE) breakdown acetylcholine neurotransmitter. inhibitors AChE can prevent excessive Monoamine oxidases brain hydrolyzing neurotransmitters such as serotonin dopamine (among others), abnormally rapid hydrolysis these via over‐activation associated with several neurodegenerative disorders including anxiety Parkinson's disease. Herein, we synthesized focused library 1,4‐dihydropyrimidines (40 compounds) using deep eutectic solvent evaluated their potential inhibit cholinesterase (AChE BChE) (MAO A MAO B) Several selective highly potent were identified; silico molecular docking dynamics simulation studies helped rationalize binding site interactions establish useful structure activity relationship. In ADME prediction data identified few could cross blood‐brain barrier, compound was selected vivo estimation LD 50 value toxicity mice, skin allergy test also carried out. All tests established safety profile compound. results encouraging enough further pursue DHPMs promising directed ligands against disorders.

Language: Английский

Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications DOI
Niraj Kumar Jha, Niraj Kumar Jha, Mohana Vamsi Nuli

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 98, P. 102224 - 102224

Published: Feb. 10, 2024

Language: Английский

Citations

14

Numerical and Analytical Simulation of the Growth of Amyloid-β Plaques DOI
A. V. Kuznetsov

Journal of Biomechanical Engineering, Journal Year: 2024, Volume and Issue: 146(6)

Published: Feb. 29, 2024

Abstract Numerical and analytical solutions were employed to calculate the radius of an amyloid-β (Aβ) plaque over time. To author's knowledge, this study presents first model simulating growth Aβ plaques. Findings indicate that can attain a diameter 50 μm after 20 years growth, provided monomer degradation machinery is malfunctioning. A mathematical incorporates nucleation autocatalytic processes using Finke–Watzky model. The resulting system ordinary differential equations was solved numerically, for simplified case infinitely long half-life, solution found. Assuming aggregates stick together distance between plaques as input parameter model, it possible from concentration aggregates. This led “cube root hypothesis,” positing size increases proportionally cube hypothesis helps explain why larger grow more slowly. Furthermore, obtained results suggest independent kinetic constants governing agglomeration, indicating kinetics agglomeration not limiting factor growth. Instead, rate limited by rates production degradation.

Language: Английский

Citations

12

Comprehensive Overview of Alzheimer’s Disease: Etiological Insights and Degradation Strategies DOI Open Access
Manish Kumar Singh,

Yoonhwa Shin,

Songhyun Ju

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(13), P. 6901 - 6901

Published: June 24, 2024

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and affects millions of individuals globally. AD associated with cognitive decline memory loss that worsens aging. A statistical report using U.S. data on estimates approximately 6.9 million suffer from AD, a number projected to surge 13.8 by 2060. Thus, there critical imperative pinpoint address its hallmark tau protein aggregation early prevent manage debilitating effects. Amyloid-β proteins are primarily formation plaques neurofibril tangles in brain. Current research efforts focus degrading amyloid-β or inhibiting their synthesis, particularly targeting APP processing hyperphosphorylation, aiming develop effective clinical interventions. However, navigating this intricate landscape requires ongoing studies trials treatments truly make difference. Genome-wide association (GWASs) across various cohorts identified 40 loci over 300 genes AD. Despite wealth genetic data, much remains be understood about functions these role process, prompting continued investigation. By delving deeper into associations, novel targets such as kinases, proteases, cytokines, degradation pathways, offer new directions for drug discovery therapeutic intervention This review delves biological pathways disrupted identifies how variations within could serve potential treatment strategies. Through comprehensive understanding molecular underpinnings researchers aim pave way more therapies can alleviate burden devastating disease.

Language: Английский

Citations

12

Digital Therapeutics for Improving Effectiveness of Pharmaceutical Drugs and Biological Products: Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases DOI Open Access

Zack Biskupiak,

Victor Vinh Ha,

Aarushi Rohaj

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(2), P. 403 - 403

Published: Jan. 11, 2024

Limitations of pharmaceutical drugs and biologics for chronic diseases (e.g., medication non-adherence, adverse effects, toxicity, or inadequate efficacy) can be mitigated by mobile medical apps, known as digital therapeutics (DTx). Authorization adjunct DTx the US Food Drug Administration draft guidelines on “prescription drug use-related software” illustrate opportunities to create + combination therapies, ultimately leading towards drug–device products (DTx has a status devices). Digital interventions (mobile, web-based, virtual reality, video game applications) demonstrate clinically meaningful benefits people living with Alzheimer’s disease, dementia, rheumatoid arthritis, cancer, pain, epilepsy, depression, anxiety. In respective animal disease models, preclinical studies environmental enrichment other non-pharmacological modalities (physical activity, social interactions, learning, music) surrogates “active ingredients” also show improved outcomes. this narrative review, we discuss how therapies impact translational research, discovery development, generic repurposing, gene therapies. Market-driven incentives are illustrated Humira® (adalimumab) facing “patent-cliff” competition cheaper more effective biosimilars seamlessly integrated DTx. conclusion, pharma biotech companies, patients, healthcare professionals will benefit from accelerating integration pharmacotherapies.

Language: Английский

Citations

11

Unveiling the Interplay: Neurovascular Coupling, Astrocytes and G Protein-Coupled Receptors in Alzheimer’s Disease DOI Creative Commons

Sanarya Al-Jaf,

Alaa Y. Soliman,

Ahmed F. El‐Yazbi

et al.

ACS Pharmacology & Translational Science, Journal Year: 2025, Volume and Issue: 8(2), P. 271 - 285

Published: Jan. 8, 2025

Astrocytes are a type of glial cell that involved in actively modulating synaptic plasticity, neurotransmitter homeostasis, and neuroinflammatory responses. More importantly, they coordinate neuronal activity cerebral blood flow (CBF) what is known as neurovascular coupling (NVC). NVC an essential mechanism maintains the high energy demand brain requires by supplying continuous rapid supply oxygen nutrients through CBF. Impairment one key events triggers spiral occurrences lead to clinical advancement Alzheimer's disease (AD). It yet be determined molecular manifestations impairment relate to; nonetheless, it believed alterations G protein-coupled receptors (GPCRs) responsible for exacerbating these effects. In this review, we summarize current evidence supporting involvement GPCRs on astrocytes pathophysiology AD. Additionally, propose potential research directions further elucidate underlying mechanisms evaluate feasibility targeting specific therapeutic strategy correct memory impairments associated with

Language: Английский

Citations

1

Multi‐Targeting Phytochemicals for Alzheimer's Disease DOI Open Access

R. Bhattacharya,

Raghuraj Singh,

Archna Panghal

et al.

Phytotherapy Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Alzheimer's disease (AD) is a type of neurodegenerative illness in which β-amyloid (Aβ) and tau protein accumulate neurons the form tangles. The pathophysiological pathway AD consists Aβ-amyloid peptides, proteins, oxidative stress increased neuro-inflammatory response. Food Drug Administration United States has authorized various drugs for effective treatment AD, include galantamine, rivastigmine, donepezil, memantine, sodium oligomannate, lecanemab, aducanumab. major disadvantage these that they only provide "symptomatic" relief. They are most early stages or mild to moderate cases disease, but not suitable long-term use. Besides conventional therapies, phytochemicals have potential stop progression AD. According research, use against gained attention due their potent anti-inflammatory, antioxidant, anti-hyperphosphorylation protein, metal chelation, anti-amyloid properties. This study seeks an up-to-date compilation current promising breakthroughs therapy using phytochemicals. It could be concluded light serve as However, more mechanistic investigations needed determine clinical implications treatment.

Language: Английский

Citations

1

Assessment of Neuroprotective Potential of Cuscuta reflexa in Aluminium Chloride-Induced Experimental Model of Alzheimer’s Disease: In Vitro and In Vivo Studies DOI

Pallavi Gangarde,

Shvetank Bhatt, Rohini Pujari

et al.

Journal of Trace Elements in Medicine and Biology, Journal Year: 2025, Volume and Issue: 88, P. 127612 - 127612

Published: Feb. 1, 2025

Language: Английский

Citations

1

Antioxidant and anti-Alzheimer's disease activities of 1,8-cineole and its cyclodextrin inclusion complex DOI Open Access
Xin Tan, Rui Xu,

А. А. Ли

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 175, P. 116784 - 116784

Published: May 22, 2024

1,8-Cineole is a bicyclic monoterpene widely distributed in the essential oils of various medicinal plants, and it exhibits significant anti-inflammatory antioxidant activities. We aimed to investigate therapeutic effect 1,8-cineole on anti-Alzheimer's disease by using transgenic Caenorhabditis elegans models. Our studies demonstrated that significantly relieved Aβ1–42-induced paralysis exhibited remarkable anti-Aβ1–42 aggregation activities nematodes CL4176, CL2006 CL2355. developed 1,8-cineole/cyclodextrin inclusion complex, displaying enhanced anti-paralysis, anti-Aβ compared 1,8-cineole. In addition, we found treatment activated SKN-1/Nrf-2 pathway induced autophagy nematodes. results 1,8-cineole, which provide potential approach for Alzheimer's disease.

Language: Английский

Citations

7

True or false? Alzheimer’s disease is type 3 diabetes: Evidences from bench to bedside DOI Creative Commons
Yong Peng,

Shun-yu Yao,

Quan Chen

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 99, P. 102383 - 102383

Published: June 30, 2024

Globally, Alzheimer's disease (AD) is the most widespread chronic neurodegenerative disorder, leading to cognitive impairment, such as aphasia and agnosia, well mental symptoms, like behavioral abnormalities, that place a heavy psychological financial burden on families of afflicted. Unfortunately, no particular medications exist treat AD, current treatments only impede its progression.The link between AD type 2 diabetes (T2D) has been increasingly revealed by research; danger developing both T2D rises exponentially with age, being especially prone AD. This propelled researchers investigate mechanism(s) underlying this connection. A critical review relationship insulin resistance, Aβ, oxidative stress, mitochondrial hypothesis, abnormal phosphorylation Tau protein, inflammatory response, high blood glucose levels, neurotransmitters signaling pathways, vascular issues in diabetes, similarities two diseases, presented review. Grasping essential mechanisms behind detrimental interaction may offer chances devise successful therapeutic strategies.

Language: Английский

Citations

7

Multi-target potential of newly designed tacrine-derived cholinesterase inhibitors: Synthesis, computational and pharmacological study DOI
Ivana Jevtić, Relja Suručić, Gordana Tovilović

et al.

Bioorganic & Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 101, P. 117649 - 117649

Published: Feb. 18, 2024

Language: Английский

Citations

6